Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Optomed Plc - Managers' transactions - Salonen

Optomed Plc - Managers' Transactions – 7 August  2023 at 16.00 EET Optomed Plc - Managers' transactions - Salonen ____________________________________________ Person subject to the notification requirement Name: Salonen, Petri Position: Member of the Board/Deputy member Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20230807115550_18 ____________________________________________ Transaction date: 2023-08-07 Venue not applicable Instrument type: SHARE ISIN: FI4000410881

Optomed Plc - Managers' transactions - Tenstam

Optomed Plc - Managers' Transactions – 7 August  2023 at 16.00 EET Optomed Plc - Managers' transactions - Tenstam ____________________________________________ Person subject to the notification requirement Name: Tenstam, Anna Position: Member of the Board/Deputy member Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20230807115550_20 ____________________________________________ Transaction date: 2023-08-07 Venue not applicable Instrument type: SHARE ISIN: FI4000410881

Change in Optomed’s holding of treasury shares

Optomed Plc Stock Exchange Release 7 August 2023 at 15.30, Helsinki Change in Optomed’s holding of treasury shares Optomed has conveyed 15,093 treasury shares to the members of the Board of Directors as a part of the Board members' annual remuneration in accordance with the decision of the Annual General Meeting 2023. The amount of shares is based on the monthly remuneration decided by the Annual General Meeting and Optomed's value weighted average share price between 28 July and 3 August 2022.     A total of 1,000 of shares have been subscribed for under the Company’s stock

Development of Alisa Bank's loan and deposit portfolio in July

ALISA BANK PLC PRESS RELEASE 7.8.2023 AT 15.30 EESTIn July 2023, Alisa Bank provided financing worth of EUR 23.9 million. The loan portfolio totaled EUR 157.8 million and deposits totaled EUR 249.4 million at the end of the month. In July, the number of customers was about 51 900. Alisa Pankki raised the interest rate on both the savings account and term deposits again in July, offering very competitive interest rates to savers. On savings account, Alisa Bank’s customers now receive 3.0% interest and on term deposits up to 3.3%, depending on the length of the deposit period. Alisa

Alisa Bank Plc will publish the January-June 2023 half-year report on Friday, 18 August 2023

ALISA BANK PLC PRESS RELEASE 7.8.2023 AT 14.45 EESTAlisa Bank Plc will publish the half-year report for the period 1 January to 30 June 2023 on Friday, 18 August 2023 at approximately 9:00 a.m. Finnish time. At that time, the half-year report is available on the company's website . Alisa Bank's CEO Teemu Nyholm will present the main points of the half-year report to analysts, investors, and the media in a webcast on the same day at 10:00 a.m. Finnish time. The webcast will be held in Finnish. At the end of the presentation,

Glaston Oyj Abp - Managers' Transactions

Glaston Corporation     Stock Exchange Release, Managers' Transactions 7.8.2023 at 14.00Glaston Oyj Abp - Managers' Transactions____________________________________________Person subject to the notification requirementName: Päivi LindqvistPosition: Chief Financial OfficerIssuer: Glaston Oyj AbpLEI: 743700V3I7CLI3DJ8L62Notification type: INITIAL NOTIFICATIONReference number: 36282/5/4 ____________________________________________Transaction date: 2023-08-03Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000369657Nature of transaction: RECEIPT OF A

Glaston Oyj Abp - Managers' Transactions

Glaston Corporation     Stock Exchange Release, Managers' Transactions  7.8.2023 at 14.00Glaston Oyj Abp - Managers' Transactions____________________________________________Person subject to the notification requirementName: Sasu KoivumäkiPosition: Other senior managerIssuer: Glaston Oyj AbpLEI: 743700V3I7CLI3DJ8L62Notification type: INITIAL NOTIFICATIONReference number: 36279/4/4 ____________________________________________Transaction date: 2023-08-03Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000369657Nature of transaction: RECEIPT OF A

Terveystalo Plc: Managers' Transactions, Juuso Pajunen

Terveystalo Plc, Managers’ transactions, 7 August 2023 at 14:00 EEST ____________________________________________ Person subject to the notification requirement Name: Juuso Pajunen Position: Chief Financial Officer Issuer: Terveystalo Oyj LEI: 7437001AEZHLL3UEX093 Notification type: INITIAL NOTIFICATION Reference number: 36249/5/4 ____________________________________________ Transaction date: 2023-08-07 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000252127 Nature of transaction: ACQUISITION ___________________________________

Navamedic ASA: Invitation to 2023 2nd quarter presentation

Oslo, August 7, 2023 - Navamedic ASA (OSE: Nava) will be presenting its second quarter 2023 results and publish its first half 2023 report on Friday, August 11, 2023. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/ For further information, please contact: Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand,CFO, +47 917 62 842 E-

Per Widerström leaves Nordnet’s Board of Directors

Board member Per Widerström has announced his intentions to leave Nordnet’s Board of Directors. Widerström has accepted the role as CEO of the gaming company 888 Holdings PLC and will not be able to commit enough time to both assignments.Per Widerström was elected as board member of Nordnet during 2017 in connection with the Nordic Capital investment and subsequent delisting from the stock exchange. In addition to being a board member, Widerström has also served as the Chairman of Nordnet’s IT Committee. Widerström will during the fall assume the role as CEO of the gaming company 888 which

#23-72 Unit issue in Hemply Balance Holding AB

The annual general meeting in Hemply Balance Holding AB (the “Company”), held on June 30, 2023, has decided on a unit issue with preferential rights for the Company’s existing shareholders.   The last day of trading in the Company’s shares including the right to receive unit rights is August 11, 2023. The first day of trading in the Company’s shares excluding the right to receive unit rights is August 14, 2023. The record date is August 15, 2023.   The shareholders of the Company will receive one (1) unit right for each (1) share held per the record date. Two (2) unit rights are

Eternali signs first customer order

Skogsaktiebolaget Eternali ("Eternali") has signed its first order for delivery of wood raw material to a customer in Europe. The buyer is BSL Comércio Internacional S.A., a Portuguese trading company that operates large volumes of wood fibre to the international market. The order is for a first shipment of 10,000 tons of wood raw material.The signed agreement with BSL is for a first order with shipment during 2023 with a value of approximately SEK 7 million. The plan for the new partnership with BSL is then to continue with ongoing deliveries by larger volumes following the first shipment.

ODI Pharma AB enters into exclusive collaboration with Synoptis Pharma Sp. z o.o.

ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has entered through its Polish subsidiary into a collaboration agreement (“Agreement”) with Synoptis Pharma Sp. Z o.o. (“Synoptis”) under which ODI becomes the exclusive supply partner for medicinal cannabis flos products to Synoptis for a period of 5 plus additional optional 3.5 years covering all Eastern and South Eastern European markets, including Poland, Czech Republic, Ukraine, Croatia etc.Milestone for ODI ODI has secured a prime pharmaceutical company in the Eastern European markets as its collaboration

BioGaia and University of Gothenburg reach an important milestone towards next-generation probiotics

In a paper published in the journal Nature, a team of researchers from the University of Gothenburg and MetaboGen, a fully owned subsidiary of BioGaia, report a novel method to overcome oxygen sensitivity to beneficial resident bacteria in the human gut, which are significantly reduced in metabolic conditions and cardiovascular disease.The gut microbiota, the trillions of microbes (bacteria, viruses, fungi, parasites, etc.)  living in our intestines, is important to digest our food, eliminate toxins, activate, and educate the immune system. In recent years, the scientific community has

SAS Traffic figures – July 2023

2.4 million passengers traveled with SAS during July2.4 million passengers traveled with SAS in July, the highest monthly passenger figure since before the pandemic. The number of passengers increased with 82 percent compared to the same month last year, which was negatively impacted by the pilot strike. SAS’ capacity increased by 84 percent and RPK by 92 percent, compared to the same month last year. The flown load factor was 86 percent during the month. “The summer season continued with another busy month for SAS. 2.4 million passengers traveled with SAS in July, the highest passenger

Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)

Stockholm, Sweden – August 7, 2023 – Biosergen AB (“Biosergen” or the “Company”), a clinical stage biotech company specializing in the development of innovative anti-fungal therapies, today announced the acceptance of an abstract for oral presentation by the Company’s Chief Operating Officer Tine Kold Olesen, PhD, MBA, at the 11th Congress on Trends in Medical Mycology (TIMM-11) to take place in Athens, Greece, from October 20-23, 2023.This abstract will feature the clinical data obtained from the recently completed Phase 1 clinical trial evaluating the safety, tolerability, and

XMReality signs new deal with Guernsey Holdings LLC

XMReality Inc., the U.S. subsidiary of XMReality AB (publ), has signed a new client deal with Guernsey Holdings LLC, a top 100 restaurant franchisee in the United States and one of the largest operators of Sonic restaurants in the country.The deal will see XMReality, Inc. provide Guernsey Holdings with its Remote Guidance™ software. The software will be used to facilitate remote collaboration between colleagues and suppliers at restaurant locations owned by Guernsey Holdings.  “We are excited to welcome Guernsey Holdings to the XMReality family,” said Ryne Simeone, Vice President of

CEO Letter #3 - Train Manager Status

Dear Trophy Games Investors, I am writing to you today to provide a status update on our newest game release, Train Manager . Since its release in mid-June, the game's launch has succeeded, with over 350,000 downloads and a July revenue of 460,000 DKK, making it our most successful release to date, and it is a testament to our developer and marketing teams' hard work and dedication. The success of Train Manager is a significant milestone for Trophy Games, as it brings us closer to our ambition of

MyFirstApp; Preliminary Revenue for July 2023

Stockholm, 2023-08-07MyFirstApp Sweden AB has obtained preliminary sales figures for the month of July. The group's sales amounted to approximately 135 TSEK (43 TSEK July 2022), an increase of 214%.This decrease in sales compared to the previous months can mainly be explained by seasonal variations that are typical for the education industry. With schools closed and learning not as prominent during the summer months, we often see a temporary decline in sales. We expect sales to recover as schools reopen and learning becomes a priority again.

XNK Therapeutics to present two abstracts at the Society for Immunotherapy of Cancer’s meeting in San Diego in November

XNK Therapeutics AB today announced that the abstracts Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer and Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment will be presented at the 38[th] Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego in November.XNK Therapeutics will participate at the SITC meeting in San Diego in November and present the latest research from the company’s leading preclinical projects in bladder cancer and acute myeloid leukemia (AML). Two abstracts

AcouSort invited to give a lecture at the Acoustofluidics conference

AcouSort’s Senior Scientist Mikael Evander has been asked to give an invited lecture at Acoustofluidics 2023, which celebrates its 20th anniversary this year. Acoustofluidics is a conference dedicated to exploring the science, the engineering, and the use of micro and nanoscale acoustofluidics. The first conference was held in 2003 as part of a UK based network called USWnet. Today, the conference has grown into an international event gathering researchers working with all different aspects of acoustofluidics and its applications within life sciences.The opportunity to give an invited

EQT Private Equity to sell Schülke, a sustainability leader in infection prevention and treatment for the healthcare industry

· EQT Private Equity to sell Schülke to the ATHOS Consortium, having acquired the Company in a carve-out from Air Liquide in July 2020. The Company has delivered double digit annual revenue growth and almost doubled EBITDA in its core healthcare business over this time  · Under EQT Private Equity’s ownership, Schülke has been repositioned to focus entirely on the healthcare and life science market, while expanding into new geographies and sales channels through five add-on acquisitions   · The Company has also established itself as a sustainability leader, for example by launching a

Repurchase of Truecaller B shares in week 31, 2023

During 31 July 2023 and 4 August 2023 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 525,000 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the share buyback programme announced by Truecaller on 7 June 2023. The share buyback programme will run between 7 June up until the 2024 AGM which will be held in May 2024, and is carried out in accordance “Emittentregelverket”.   On the Annual General Meeting 2023 the Board was authorized to buy back B-shares up until the

Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the formation of a Scientific Advisory Council as the company intensifies its plans for next phase of development. In February, Medivir announced positive, preliminary results from the dose escalation cohorts of its candidate drug fostrox, in combination with Lenvima® and initiated the phase 2a expansion cohort. Fostrox, designed to selectively treat liver cancers while minimizing systemic side

There are no items matching the current filter
There are no more items matching the current filter
Back to top